Silexion Therapeutics LTD (SLXNW)
NASDAQ: SLXNW
· Real-Time Price · USD
0.07
0.00 (1.01%)
At close: Jun 09, 2025, 9:30 AM
Silexion Therapeutics LTD Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -11.32M | -11.32M | -11.15M | -3.84M | -2.61M | -3.05M | -1.81M | -1.32M | -1.32M | -1.23M | -1.18M | -940.63K | -978.69K | -721.11K | -483.57K | -483.57K | -288.51K |
Interest Income | 6K | 25K | 58K | 100K | 412K | 1.14M | 2.1M | 2.58M | 2.42M | 1.69M | 694.93K | 176.68K | 15.08K | 6.37K | 4.19K | 2.42K | 676.00 |
Pretax Income | -11.98M | -15.13M | -15.06M | -4.01M | -3.73M | -2M | 167.56K | 1.26M | 1.14M | 584.02K | -152.15K | -668.64K | -903.12K | -755.22K | -709.31K | -485.41K | -293.61K |
Net Income | -13.34M | -16.44M | -16.42M | -5.36M | -3.73M | -2.04M | 183.56K | 1.26M | 1.14M | 584.02K | -152.15K | -668.64K | -903.12K | -755.22K | -709.31K | -485.41K | -293.61K |
Selling & General & Admin | 7.54M | 6.76M | 6.18M | 1.55M | 1.09M | 1.24M | 1.27M | 1.32M | 1.32M | 1.23M | 1.18M | 940.63K | 978.69K | 721.11K | 483.57K | 483.57K | 288.51K |
Research & Development | 5.44M | 5.82M | 6.2M | 3.52M | 2.75M | 1.79M | 535K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Expenses | -8K | n/a | 14K | 24K | 24K | 16K | 10K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 12.97M | 12.57M | 12.4M | 5.09M | 3.86M | 3.05M | 1.81M | 1.32M | 1.32M | 1.23M | 1.18M | 940.63K | 978.69K | 721.11K | 483.57K | 483.57K | 288.51K |
Interest Expense | 2K | 2K | -41K | 4K | 2K | 2K | 45K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 11.32M | 12.57M | 12.4M | 5.09M | 3.55M | 1.87M | -349.31K | -1.32M | -1.32M | -1.23M | -1.18M | -940.63K | -978.69K | -721.11K | -483.57K | -483.57K | -288.51K |
Income Tax Expense | 1K | 6K | 11K | 15K | 17K | 12K | 6K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 6.78M | 1.85M | 647.57K | 430K | 430K | 430K | 552.77K | 660.51K | 1.21M | 1.65M | 1.65M | 1.65M | 1.65M | 1.65M | 1.65M | 1.65M | 1.65M |
Shares Outstanding (Diluted) | 6.78M | 1.85M | 647.57K | 430K | 430K | 430K | 552.77K | 660.51K | 1.21M | 1.65M | 1.65M | 1.65M | 1.65M | 1.65M | 1.65M | 1.65M | 1.65M |
EPS (Basic) | -21.01 | -21.74 | -19.71 | -1.26 | -0.75 | -0.03 | 0.94 | 0.98 | 0.76 | 0.35 | -0.09 | -0.41 | -0.55 | -0.46 | -0.43 | -0.29 | -0.18 |
EPS (Diluted) | -21.01 | -21.74 | -19.71 | -1.26 | -0.97 | -0.25 | 0.45 | 0.34 | 0.34 | -0.07 | -0.12 | -0.28 | -0.42 | -0.33 | -0.32 | -0.19 | -0.07 |
EBITDA | -11.24M | -12.48M | -12.46M | -5.16M | -3.52M | -1.97M | 249.56K | 1.26M | 1.14M | 584.02K | -152.15K | -668.63K | -903.12K | -755.22K | -709.31K | -485.41K | -293.61K |
EBIT | -15.35M | -16.6M | -12.5M | -5.19M | -3.55M | -1.98M | 239.56K | 1.26M | 1.14M | 584.02K | -152.15K | -668.63K | -903.12K | -755.22K | -709.31K | -485.41K | -293.61K |
Depreciation & Amortization | -1K | 7K | 43K | 31K | 342.42K | 1.08M | 2.06M | 2.58M | 2.46M | 1.82M | 1.03M | 495.89K | 299.47K | 189.8K | -1.83K | -1.83K | -5.1K |